Sean Edelstein, MD
Ophthalmology · Saint Louis, MONPI 1679520605
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,349 of the $8,515 with a category attached, or 86.3%. 25 manufacturers reported payments, led by Alcon at 26.1% of the total. Reporting peaked in 2019 at $2,815 and has fallen 66.1% since, to $953 in 2025.
Across 167 payments — averaging $50.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- Johnson & Johnson Surgical Vision, Inc.$2K
- Biotissue Holdings Inc.$884
- Oyster Point Pharma, Inc.$586
- Tarsus Pharmaceuticals, Inc.$356
- Sun Pharmaceutical Industries Inc.$287
- plus $2K from 19 others
What the payments were for
- Travel & lodging$1,16614%
- Food & beverage$7,34986%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 33 | $2,218 |
| Johnson & Johnson Surgical Vision, Inc. | 12 | $2,075 |
| Biotissue Holdings Inc. | 23 | $884 |
| Oyster Point Pharma, Inc. | 6 | $586 |
| Tarsus Pharmaceuticals, Inc. | 9 | $356 |
| Sun Pharmaceutical Industries Inc. | 14 | $287 |
| AbbVie(2 entities) | 9 | $260 |
| Mallinckrodt Hospital Products Inc. | 5 | $237 |
| Glaukos Corporation | 7 | $225 |
| Bausch & Lomb Americas Inc. | 6 | $207 |
| Aerie Pharmaceuticals, Inc. | 5 | $177 |
| Novartis | 8 | $148 |
| Rxsight Inc | 1 | $144 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $132 |
| Shire North American Group Inc | 8 | $128 |
| Sight Sciences, Inc. | 3 | $119 |
| Eyevance Pharmaceuticals LLC | 1 | $114 |
| Amgen(2 entities) | 2 | $49 |
| Kala Pharmaceuticals, Inc. | 2 | $39 |
| Dompe US, Inc. | 1 | $26 |
| Thea Pharma Inc. | 1 | $23 |
| Harrow Eye, LLC | 1 | $23 |
| Astellas Pharma US Inc | 1 | $22 |
| Ivantis, Inc | 1 | $21 |
| Ocular Therapeutix, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Premium Cataract IOLs$1,411
- TYRVAYA$535
- Clareon$491
- AcrySof$364
- Tecnis IOL$311
- Unity$292
- RXSIGHT CONTACT LENS$144
- RXSIGHT INJECTOR CARTRIDGE$144
- RXSIGHT INJECTOR HANDPIECE$144
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$144
- LIGHT ADJUSTABLE LENS (LAL)$144
- ARGOS$137
- AcrySof IQ PanOptix UV IOL$128
- AcrySof IQ VIVITY$128
- Tecnis Multifocal Family of 1-piece IOLS$125
- CEQUA$124
- XDEMVY$123
- ACTHAR$123
- AcrySof IQ PanOptix$122
- VUITY$121
How this compares
$8,515 in reported general payments places this provider in the 85th percentile of 286 ophthalmology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 45 | $45,482 |
| Prednisolone Acetate | 606 | $27,818 |
| Cyclosporine | 42 | $23,295 |
| XiidraLifitegrast | 25 | $17,842 |
| MieboPerfluorohexyloctane/Pf | 12 | $15,266 |
| Loteprednol Etabonate | 89 | $12,636 |
| RhopressaNetarsudil Mesylate | 28 | $8,897 |
| Brimonidine Tartrate | 123 | $8,719 |
| LumiganBimatoprost | 23 | $8,399 |
| Fluorometholone | 46 | $4,663 |
| Alphagan PBrimonidine Tartrate | 17 | $3,792 |
| Ofloxacin | 313 | $3,504 |
| Ketorolac Tromethamine | 228 | $3,343 |
| CombiganBrimonidine Tartrate/Timolol | 11 | $3,135 |
| Dexamethasone Sodium Phosphate | 76 | $3,023 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P, Combigan | $260 | $60,80896 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $207 | $33,10937 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $132 | $12,63689 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $177 | $8,89728 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 286 ophthalmology providers in Missouri.
Other ophthalmology in Saint Louis
- Ranjan MalhotraSaint Louis$809K
- Gregg BerdySaint Louis$360K
- Rajendra ApteSaint Louis$112K
- Ian PithaSaint Louis$85K
- Senthil KrishnasamySaint Louis$46K
- Navin TekwaniSaint Louis$34K
- Steven LeeSaint Louis$33K
- John GalanisSaint Louis$20K
- Bruce CohenSaint Louis$11K
- Waseem AnsariSaint Louis$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.